Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity

Daan van den Broek, T Jeroen N Hiltermann, Bonne Biesma, Winand N M Dinjens, Nils A 't Hart, John W J Hinrichs, Mathie P G Leers, Kim Monkhorst, Matthijs van Oosterhout, Volkher Scharnhorst, Ed Schuuring, Ernst-Jan M Speel, Michel M van den Heuvel, Ron H N van Schaik, Jan von der Thüsen, Stefan M Willems, Leonie de Visser, Marjolijn J L Ligtenberg, Daan van den Broek, T Jeroen N Hiltermann, Bonne Biesma, Winand N M Dinjens, Nils A 't Hart, John W J Hinrichs, Mathie P G Leers, Kim Monkhorst, Matthijs van Oosterhout, Volkher Scharnhorst, Ed Schuuring, Ernst-Jan M Speel, Michel M van den Heuvel, Ron H N van Schaik, Jan von der Thüsen, Stefan M Willems, Leonie de Visser, Marjolijn J L Ligtenberg

Abstract

The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly with the availability of novel treatments. Despite high-level healthcare in the Netherlands, not all patients with NSCLC are tested with the currently relevant predictive tumor markers that are necessary for optimal decision-making for today's available targeted or immunotherapy. An expert workshop on the molecular diagnosis of NSCLC involving pulmonary oncologists, clinical chemists, pathologists, and clinical scientists in molecular pathology was held in the Netherlands on December 10, 2018. The aims of the workshop were to facilitate cross-disciplinary discussions regarding standards of practice, and address recent developments and associated challenges that impact future practice. This paper presents a summary of the discussions and consensus opinions of the workshop participants on the initial challenges of harmonization of the detection and clinical use of predictive markers of NSCLC. A key theme identified was the need for broader and active participation of all stakeholders involved in molecular diagnostic services for NSCLC, including healthcare professionals across all disciplines, the hospitals and clinics involved in service delivery, healthcare insurers, and industry groups involved in diagnostic and treatment innovations. Such collaboration is essential to integrate different technologies into molecular diagnostics practice, to increase nationwide patient access to novel technologies, and to ensure consensus-preferred biomarkers are tested.

Keywords: carcinoma; molecular pathology; molecular targeted therapy; non-small cell lung; precision medicine; predictive tumor markers.

Copyright © 2020 van den Broek, Hiltermann, Biesma, Dinjens, 't Hart, Hinrichs, Leers, Monkhorst, van Oosterhout, Scharnhorst, Schuuring, Speel, van den Heuvel, van Schaik, von der Thüsen, Willems, de Visser and Ligtenberg.

References

    1. Tsao AS, Scagliotti GV, Bunn PA, Jr, Carbone DP, Warren GW, Bai C, et al. . Scientific advances in lung cancer 2015. J Thorac Oncol. (2016) 11:613–38. 10.1016/j.jtho.2016.03.012
    1. Economopoulou P, Mountzios G. The emerging treatment landscape of advanced non-small cell lung cancer. Ann Transl Med. (2018) 6:138. 10.21037/atm.2017.11.07
    1. Janssen-Heijnen ML, van Steenbergen LN, Steyerberg E, Visser O, De Ruysscher DK, Groen HJ. Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands. J Thorac Oncol. (2012) 7:496–502. 10.1097/JTO.0b013e318241f80b
    1. Peters BJM, Cramer-Vd Welle CM, Smit AAJ, Schramel FMNH, van de Garde EMW, Santeon NSCLC Study Group Trends in prescribing systematic treatment and overall survival for non-small cell lung cancer stage IIIB/IV in the Netherlands: 2008–12. Cancer Epidemiol. (2017) 51:1–6. 10.1016/j.canep.2017.08.001
    1. Caballero Vázquez A, García Flores P, Romero Ortiz A, Del Moral RG, Alcázar-Navarrete B. Changes in non-small cell lung cancer diagnosis, molecular testing and prognosis 2011-2016. J Thorac Dis. (2018) 10:5468–75. 10.21037/jtd.2018.08.49
    1. McLean AEB, Barnes DJ, Troy LK. Diagnosing lung cancer: the complexities of obtaining a tissue diagnosis in the era of minimally invasive and personalised medicine. J Clin Med. (2018) 7:E163. 10.3390/jcm7070163
    1. Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer: recent advances and future perspectives. Int J Cancer. (2016) 138:2549–61. 10.1002/ijc.29915
    1. Loong HH, Kwan SS, Mok TS, Lau YM. Therapeutic strategies in EGFR mutant non-small cell lung cancer. Curr Treat Options Oncol. (2018) 19:58. 10.1007/s11864-018-0570-9
    1. Kuijpers CCHJ, van den Heuvel MM, Overbeek LIH, van Slooten HJ, van Lindert ASR, Damhuis RAM, et al. . National variation in molecular diagnostics in metastatic lung cancer. Ned Tijdschr Geneeskd. (2018) 162:D1607.
    1. Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A, et al. . PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget. (2016) 7:19738–47. 10.18632/oncotarget.7582
    1. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. . NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. (2018) 16:807–21. 10.6004/jnccn.2018.0062
    1. VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, et al. . Tumor biomarker testing in non-small-cell lung cancer: a decade of change. Lung Cancer. (2018) 116:90–5. 10.1016/j.lungcan.2018.01.002
    1. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. . Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. (2018) 13:323–58. 10.1016/j.jtho.2017.12.001
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al. . Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. (2016) 375:1823–33. 10.1056/NEJMoa1606774
    1. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. . PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 Assay Comparison Project. J Thorac Oncol. (2017) 12:208–22. 10.1016/j.jtho.2016.11.2228
    1. Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scott M, Scorer P, et al. . Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res. (2017) 23:3585–91. 10.1158/1078-0432.CCR-16-2375
    1. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, et al. . A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. (2017) 3:1051–8. 10.1001/jamaoncol.2017.0013
    1. Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, et al. . PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. J Thorac Oncol. (2018) 13:1302–11. 10.1016/j.jtho.2018.05.013
    1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. . Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. (2018) 378:2078–92. 10.1056/NEJMoa1801005
    1. European Medicines Agency Imfinzi [durvalumab]: EPAR - Product Information. (2018) Available online at: (accessed May 20, 2019).
    1. Dempke WCM, Fenchel K, Dale SP. Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment: are we barking up the wrong tree? Transl Lung Cancer Res. (2018) 7(Suppl. 3):S275–9. 10.21037/tlcr.2018.04.18
    1. Deans ZC, Butler R, Cheetham M, Dequeker EMC, Fairley JA, Fenizia F, et al. . IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. Virchows Arch. (2019) 474:681–9. 10.1007/s00428-019-02571-3
    1. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. (2019) 20:71–88. 10.1038/s41576-018-0071-5
    1. Keppens C, Dequeker EMC, Patton SJ, Normanno N, Fenizia F, Butler R, et al. . International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA. BMC Cancer. (2018) 18:804. 10.1186/s12885-018-4694-x
    1. Keppens C, Tack V, 't Hart N, Tembuyser L, Ryska A, Pauwels P, et al. . A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer. Oncotarget. (2018) 9:20524–38. 10.18632/oncotarget.24980
    1. Saarenheimo J, Eigeliene N, Andersen H, Tiirola M, Jekunen A. The value of liquid biopsies for guiding therapy decisions in non-small cell lung cancer. Front Oncol. (2019) 9:129. 10.3389/fonc.2019.00129
    1. Mehrad M, Roy S, Bittar HT, Dacic S. Next-generation sequencing approach to non-small cell lung carcinoma yields more actionable alterations. Arch Pathol Lab Med. (2018) 142:353–7. 10.5858/arpa.2017-0046-OA
    1. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. . Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. (2018) 36:1631–41. 10.1200/JCO.2017.76.8671
    1. Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, et al. . Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. (2019) 5:173–80. 10.1001/jamaoncol.2018.4305
    1. Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, et al. A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers. J Natl Cancer Inst. (2019) 111:575–83. 10.1093/jnci/djy156
    1. Brown NA, Aisner DL, Oxnard GR. Precision medicine in non-small cell lung cancer: current standards in pathology and biomarker interpretation. Am Soc Clin Oncol Educ Book. (2018) 38:708–15. 10.1200/EDBK_209089
    1. Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, García RC, et al. . Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. (2016) 71:177–84. 10.1136/thoraxjnl-2014-206677
    1. McCall SJ, Dry SM. Precision pathology as part of precision medicine: are we optimizing patients' interests in prioritizing use of limited tissue samples? JCO Precis Oncol. (2019) 3:1–6. 10.1200/PO.18.00238
    1. Roemen GMJM, zur Hausen A, Speel EJM. Adequate tissue for adequate diagnosis: what do we really need? In: Dingemans AMC, Reck M, Westeel V. editors. Lung Cancer (ERS Monographs, Vol. 68). Sheffield: European Respiratory Society; (2015). p. 119–35.
    1. Deans ZC, Costa JL, Cree I, Dequeker E, Edsjö A, Henderson S, et al. . Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. Virchows Arch. (2017) 470:5–20. 10.1007/s00428-016-2025-7
    1. Tack V, Schuuring E, Keppens C, 't Hart N, Pauwels P, van Krieken H, et al. . Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. Br J Cancer. (2018) 119:605–14. 10.1038/s41416-018-0204-9
    1. Integraal Kankercentrum Nederland Landelijke Richtlijn: Niet Kleincellig Longcarcinoom [Netherlands' national guidelines: non-small cell lung cancer; in Dutch] [Version 2.3]. (2015) Available online at: (accessed November 20, 2019).
    1. Doroshow DB, Herbst RS. Treatment of advanced non-small lung cancer in 2018. JAMA Oncol. (2018) 4:569–70. 10.1001/jamaoncol.2017.5190
    1. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. . Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2018) 29(Suppl. 4):iv192–237. 10.1093/annonc/mdy275
    1. Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC – challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. (2018) 15:577–86. 10.1038/s41571-018-0058-3
    1. Zhang YC, Zhou Q, Wu YL. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer. J Hematol Oncol. (2017) 10:167. 10.1186/s13045-017-0536-6
    1. Bernabé R, Hickson N, Wallace A, Blackhall FH. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer? Eur J Cancer. (2017) 81:66–73. 10.1016/j.ejca.2017.04.022
    1. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. . Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. (2016) 34:3375–82. 10.1200/JCO.2016.66.7162
    1. Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. . Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. (2019) 25:4691–700. 10.1158/1078-0432.CCR-19-0624
    1. Ohira T, Sakai K, Matsubayashi J, Kajiwara N, Kakihana M, Hagiwara MM, et al. . Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer. Cancer Sci. (2016) 107:1660–6. 10.1111/cas.13068
    1. Oellerich M, Schütz E, Beck J, Walson PD. Circulating cell-free DNA: diagnostic and prognostic applications in personalized cancer therapy. Ther Drug Monit. (2019) 41:115–20. 10.1097/FTD.0000000000000566
    1. Bracht JWP, Mayo-de-Las-Casas C, Berenguer J, Karachaliou N, Rosell R. The present and future of liquid biopsies in non-small cell lung cancer: combining four biosources for diagnosis, prognosis, prediction, and disease monitoring. Curr Oncol Rep. (2018) 20:70. 10.1007/s11912-018-0720-z
    1. IJzerman MJ, Berghuis AMS, de Bono JS, Terstappen LWMM. Health economic impact of liquid biopsies in cancer management. Expert Rev Pharmacoecon Outcomes Res. (2018) 18:593–9. 10.1080/14737167.2018.1505505
    1. Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J. (2018) 16:370–8. 10.1016/j.csbj.2018.10.002
    1. Normanno N, Pinto C, Taddei G, Gambacorta M, Castiglione F, Barberis M, et al. . Results of the first Italian external quality assurance scheme for somatic EGFR mutation testing in non-small-cell lung cancer. J Thorac Oncol. (2013) 8:773–8. 10.1097/JTO.0b013e31828c2b08
    1. Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, et al. . Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br Cancer J. (2014) 111:413–20. 10.1038/bjc.2014.353
    1. Lam A, Yoshida EJ, Bui K, Katrivesis J, Fernando D, Nelson K, et al. . Patient and facility demographics related outcomes in early-stage non-small cell lung cancer treated with radiofrequency ablation: a National Cancer Database analysis. J Vasc Interv Radiol. (2018) 29:1535–41. 10.1016/j.jvir.2018.06.005
    1. van Erning FN, van Steenbergen LN, van den Broek WT, Rutten HJ, Lemmens VE. No difference between lowest and highest volume hospitals in outcome after colorectal cancer surgery in the southern Netherlands. Eur J Surg Oncol. (2013) 39:1199–206. 10.1016/j.ejso.2013.08.020
    1. Haj Mohammad N, Bernards N, Besselink MG, Busch OR, Wilmink JW, Creemers GJ, et al. . Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. J Cancer Res Clin Oncol. (2016) 142:1353–60. 10.1007/s00432-016-2140-5
    1. Hamblin A, Wordsworth S, Fermont JM, Page S, Kaur K, Camps C, et al. . Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: retrospective validation and prospective audit in the UK National Health Service. PLoS Med. (2017) 14:e1002230. 10.1371/journal.pmed.1002230
    1. Joosten SEP, Retel VP, Coupe VMH, van den Heuvel MM, van Harten WH. Scenario drafting for early technology assessment of next generation sequencing in clinical oncology. BMC Cancer. (2016) 16:66. 10.1186/s12885-016-2100-0
    1. Garfield S, Polisena J, Spinner DS, Postulka A, Lu CY, Tiwana SK, et al. . Health technology assessment for molecular diagnostics: practices, challenges, and recommendations from the Medical Devices and Diagnostics Special Interest Group. Value Health. (2016) 19:577–87. 10.1016/j.jval.2016.02.012
    1. Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. . NSCLC molecular testing in Central and Eastern European countries. BMC Cancer. (2018) 18:269. 10.1186/s12885-018-4023-4
    1. Dacic S. Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol. (2013) 66:870–4. 10.1136/jclinpath-2012-201336
    1. Levy B, Hu ZI, Cordova KN, Close S, Lee K, Becker D. Clinical utility of liquid diagnostic platforms in non-small cell lung cancer. Oncologist. (2016) 21:1121–30. 10.1634/theoncologist.2016-0082
    1. Sholl L. Molecular diagnostics of lung cancer in the clinic. Transl Lung Cancer Res. (2017) 6:560–9. 10.21037/tlcr.2017.08.03
    1. Brainard J, Farver C. The diagnosis of non-small cell lung cancer in the molecular era. Mod Pathol. (2019) 32(Suppl. 1):16–26. 10.1038/s41379-018-0156-x
    1. Tate JR, Myers GL. Harmonization of clinical laboratory test results. J Int Fed Clin Chem Lab Med. (2016) 27:5–14.
    1. Li CM, Chu WY, Wong DL, Tsang HF, Tsui NB, Chan CM, et al. . Current and future molecular diagnostics in non-small-cell lung cancer. Expert Rev Mol Diagn. (2015) 15:1061–74. 10.1586/14737159.2015.1063420
    1. Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, et al. . Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3,000 Heidelberg cases. Int J Cancer. (2019) 145:649–61. 10.1002/ijc.32133
    1. Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Tsongalis GJ, Rademaker AW, et al. . Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst. (2014) 106:dju256. 10.1093/jnci/dju256

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe